PPARγ antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis

Barak, 1999, PPAR gamma is required for placental, cardiac, and adipose tissue development, Mol. Cell, 4, 585, 10.1016/S1097-2765(00)80209-9 Barroso, 1999, Dominant negative mutations in human PPAR gamma associated with severe insulin resistance, diabetes mellitus and hypertension, Nature, 402, 880, 10.1038/47254 Bitsch, 2002, Differentiation of multiple sclerosis subtypes: implications for treatment, CNS Drugs, 6, 405, 10.2165/00023210-200216060-00004 Blumberg, 1998, Orphan nuclear receptors: new ligands and new possibilities, Genes Dev., 12, 3149, 10.1101/gad.12.20.3149 Bright, 1998, Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalomyelitis, J. Neuroimmunol., 82, 22, 10.1016/S0165-5728(97)00184-7 Bright, 1999, Differential influence of interleukin-12 in the pathogenesis of autoimmune and virus-induced CNS demyelination, J. Virol., 3, 1637, 10.1128/JVI.73.2.1637-1639.1999 Chawla, 2001, PPARγ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation, Nat. Med., 7, 48, 10.1038/83336 Chu, 2000, Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis, J. Exp. Med., 192, 123, 10.1084/jem.192.1.123 Coleman, 2002, Axon pathology in neurological disease: a neglected therapeutic target, Trends Neurosci., 25, 532, 10.1016/S0166-2236(02)02255-5 Cua, 2003, Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain, Nature, 6924, 744, 10.1038/nature01355 Dean, 1994, How many people in the world have MS?, Neuroepidemiology, 13, 1, 10.1159/000110351 Demetri, 1999, Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma, Proc. Natl. Acad. Sci. U. S. A., 96, 3951, 10.1073/pnas.96.7.3951 Diab, 2002, Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis, J. Immunol., 168, 2508, 10.4049/jimmunol.168.5.2508 Elbrecht, 1996, Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2, Biochem. Biophys. Res. Commun., 224, 431, 10.1006/bbrc.1996.1044 Elstner, 1998, Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice, Proc. Natl. Acad. Sci. U. S. A., 95, 8806, 10.1073/pnas.95.15.8806 Evans, 1988, The steroid and thyroid hormone receptor superfamily, Science, 240, 889, 10.1126/science.3283939 Feinstein, 2002, Peroxisome proliferator activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis, Ann. Neurol., 51, 694, 10.1002/ana.10206 Ferber, 1996, Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE), J. Immunol., 156, 5, 10.4049/jimmunol.156.1.5 Forman, 1995, 15-Deoxy-12,14 prostaglandin J2 a ligand for the adipocyte determination factor PPAR gamma, Cell, 83, 803, 10.1016/0092-8674(95)90193-0 Franklin, 2002, Why does remyelination fail in multiple sclerosis?, Nat. Rev., Neurosci., 3, 705, 10.1038/nrn917 Gold, 2000, Animal models for autoimmune demyelinating disorders of the nervous system, Mol. Med. Today, 6, 88, 10.1016/S1357-4310(99)01639-1 Hemmer, 2002, New concepts in the immunopathogenesis of multiple sclerosis, Nat. Rev., Neurosci., 4, 291, 10.1038/nrn784 Jiang, 1998, PPARγ agonists inhibit production of monocyte inflammatory cytokine, Nature, 391, 82, 10.1038/35154 Kawahito, 2000, 15-Deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats, J. Clin. Invest., 106, 189, 10.1172/JCI9652 Kliewer, 1998, The nuclear receptor PPAR-bigger than fat, Curr. Opin. Genet. Dev., 8, 576, 10.1016/S0959-437X(98)80014-2 Krey, 1997, Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay, Mol. Endocrinol., 11, 779, 10.1210/me.11.6.779 Lehmann, 1995, An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARγ), J. Biol. Chem., 270, 12953, 10.1074/jbc.270.22.12953 Mukherjee, 1997, Identification, characterization and tissue distribution of human peroxisome proliferator activated receptor isoforms 1 and 2 and activation with retinoid×receptor agonists and antagonists, J. Biol. Chem., 272, 8071, 10.1074/jbc.272.12.8071 Nagy, 1998, Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma, Cell, 93, 229, 10.1016/S0092-8674(00)81574-3 Natarajan, 2002, Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation, Genes Immun., 3, 59, 10.1038/sj.gene.6363832 Natarajan, 2003, Peroxisome proliferator-activated receptor-gamma deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis, J. Immunol., 171, 5743, 10.4049/jimmunol.171.11.5743 Nencioni, 2003, Role of peroxisome proliferator-activated receptor gamma and its ligands in the control of immune responses, Crit. Rev. Immunol., 23, 1, 10.1615/CritRevImmunol.v23.i12.10 Neve, 2000, Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis, Biochem. Pharmacol., 60, 1245, 10.1016/S0006-2952(00)00430-5 Niino, 2001, Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of PPARγ, J. Neuroimmunol., 116, 40, 10.1016/S0165-5728(01)00285-5 Noseworthy, 2000, Multiple sclerosis, N. Engl. J. Med., 343, 938, 10.1056/NEJM200009283431307 Owens, 1995, The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis, Neurol. Clin., 13, 51, 10.1016/S0733-8619(18)30061-6 Ricote, 1998, The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation, Nature, 391, 79, 10.1038/34178 Schmidt, 2004, Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients, J. Leukoc. Biol., 75, 478, 10.1189/jlb.0803402 Schwartz, 1998, Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group, N. Engl. J. Med., 338, 861, 10.1056/NEJM199803263381302 Spiegelman, 1998, PPARγ in monocytes—less pain, any gain?, Cell, 93, 153, 10.1016/S0092-8674(00)81567-6 Steinman, 2002, Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy, Annu. Rev. Neurosci., 25, 491, 10.1146/annurev.neuro.25.112701.142913 Tran, 2000, IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines, J. Immunol., 164, 2759, 10.4049/jimmunol.164.5.2759 Willenborg, 1996, IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis, J. Immunol., 157, 3223, 10.4049/jimmunol.157.8.3223 Willson, 1997, Peroxisome proliferator activated receptor agonists, Curr. Opin. Chem. Biol., 1, 235, 10.1016/S1367-5931(97)80015-4 Wingerchuk, 2001, Multiple sclerosis: current pathophysiological concepts, Lab. Invest., 81, 263, 10.1038/labinvest.3780235